Principal Financial Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Principal Financial Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$207K	Buy	+3,241	New	+$168K	﹤0.01%	2087
2025 Q2	–	Sell	-27,082	Closed	-$601K	–	2272
2025 Q1	$601K	Buy	27,082 +175	+0.7%	+$3.6K	﹤0.01%	1910
2024 Q4	$532K	Sell	26,907 -25,944	-49%	-$592K	﹤0.01%	1952
2024 Q3	$1.32M	Sell	52,851 -14,100	-21%	-$343K	﹤0.01%	1821
2024 Q2	$1.25M	Buy	66,951 +7,960	+13%	+$149K	﹤0.01%	1832
2024 Q1	$1.16M	Buy	58,991 +17,659	+43%	+$345K	﹤0.01%	1849
2023 Q4	$725K	Sell	41,332 -3,392	-8%	-$55.8K	﹤0.01%	1881
2023 Q3	$777K	Buy	+44,724	New	+$753K	﹤0.01%	1874

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Principal Financial Group's KNSA Position: Q2 2026 in Review

Principal Financial Group opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 3,241 shares worth $207K. The stake represents ﹤0.01% of the portfolio and ranks #2087 among its holdings. This is a return to the name: Principal Financial Group previously reported a position in KNSA as recently as Q1 2025.

Principal Financial Group first reported a position in KNSA in Q3 2023 and has held it in 8 quarters since. The position peaked at $1.32M in Q3 2024. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Principal Financial Group held 3,241 shares of Kiniksa Pharmaceuticals worth $207K as of Q2 2026.
Kiniksa Pharmaceuticals was a new Principal Financial Group position in Q2 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2087 holding.
Principal Financial Group first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
Principal Financial Group's Kiniksa Pharmaceuticals position peaked at $1.32M in Q3 2024.
267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.